Oocyte cryopreservation

Gonadal Tissue Cryopreservation in Fertility Preservation

Volumn , Issue , 2016, Pages 1-19

  Domingo, Javier ^a   Cobo, Ana ^b   Pellicer, Antonio ^c,d  

^a IVI Las Palmas   (Spain)

^b IVI Valencia   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d University Medical   (Spain)

Author keywords

Cryopreservation; Fertility preservation; Oocyte; Vitrification

Indexed keywords

EID: 85019859518     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-4-431-55963-4_1     Document Type: Chapter

References (74)

1. Surveillance, Epidemiology and End Results Program, 1975-2003, Division of Cancer Control and Population Sciences, National Cancer Institute, 2006
2. http://www.uv.es/rnti/cifrasCancer.html
3. Domingo J, Cobo A, Sanchez M et al (2011) Principles and practice of fertility preservation. In: Donnez, Kim (eds) Principles and practice of fertility preservation. Cambridge University Press, New York, pp 23-34
4. Cobo A, Domingo J, Perez S et al (2008) Vitrification: an effective new approach to oocyte banking and preserving fertility in cancer patients. Clin Transl Oncol 10:268-273
5. Jeruss JS, Woodruff TK (2009) Preservation of fertility in patients with cancer. N Engl J Med 360:902-911. doi:10.1056/NEJMra0801454
6. Humaidan P, Kol S, Papanikolaou EG (2011) GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update 17:510-524. doi:10.1093/ humupd/dmr008
7. Ethics Committee of the American Society for Reproductive Medicine (2005) Fertility preservation and reproduction in cancer patients. Fertil Steril 83:1622-1628
8. The Practice Committees of the ASRM and SART (2013) Mature oocyte cryopreservation: a guideline. Fertil Steril 99:37-43. doi:10.1016/j.fertnstert.2012.09.028
9. Dolmans MM, Luyckx V, Donnez J et al (2013) Risk of transferring malignant cells with transplanted frozen thawed ovarian tissue. Fertil Steril 99:1514-1522. doi:10.1016/j.fertnstert. 2013.03.027
10. Cao Y, Xing Q, Zhang ZG et al (2009) Cryopreservation of immature and in vitro matured oocytes by vitrification. Reprod Biomed Online 19:369-373
11. Cobo A, Diaz C (2011) Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril 96:277-285. doi:10.1016/j. fertnstert.2011.06.030
12. Cobo A, Kuwayama M, Perez S et al (2008) Companson of concomitant outcome achieved with fresh and cryopreserved oocytes vitrified by the Cryotop method. Fertil Steril 89:1657-1664
13. Kuwayama M, Vajta G, Kato O et al (2005) Highly efficient vitrification method for cryopreservation of human oocytes. Reprod Biomed Online 11:300-308
14. Tao T, del Valle A (2008) Human oocyte and ovarian tissue cryopreservation and its application. J Assist Reprod Genet 25:287-296. doi:10.1007/s10815-008-9236-z
15. Vajta G, Nagy ZP (2006) Are programmable freezers still needed in the embryo laboratory? Review on vitrification. Reprod Biomed Online 12:779-796
16. Cobo A, Meseguer M, Remohi J et al (2010) Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. Hum Reprod 25:2239-2246. doi: 10.1093/humrep/deq146
17. Bielawski A, Nadin-Davis S, Sapp T et al (2000) Viral contamination of embryos cryopreserved in liquid nitrogen. Cryobiology 40:110-116
18. Parmegiani L, Accorsi A, Cognigni GE et al (2010) Sterilization of liquid nitrogen with ultraviolet irradiation for safe vitrification of human oocytes or embryos. Fertil Steril 94:1525-1528. doi:10.1016/j.fertnstert.2009.05.089
19. Cobo A, Romero JL, Perez S et al (2010) Storage of human oocytes in the vapor phase of nitrogen. Fertil Steril 94:1903-1907. doi:10.1016/j.fertnstert.2009.10.042
20. Boiso I, Marti M, Santalo J et al (2002) A confocal microscopy analysis of the spindle and chromosome configurations of human oocytes cryopreserved at the germinal vesicle and metaphase II stage. Hum Reprod 17:1885-1891
21. Forman EJ, Li X, Ferry KM et al (2012) Oocyte vitrification does not increase the risk of embryonic aneuploidy or diminish the implantation potential of blastocysts created after ICSI: a novel, paired randomized controlled trial using DNA fingerprinting. Fertil Steril 98:644-649. doi:10.1016/j.fertnstert.2012.04.028
22. Cobo A, Rubio C, Gerli S et al (2001) Use of fluorescence in situ hybridization to assess the chromosomal status of embryos obtained from cryopreserved oocytes. Fertil Steril 75:354-360
23. Cobo A, Píírez S, De los Saltos MJ et al (2008) Effect of different cryopreservation protocols on the metaphase II spindle in human oocytes. Reprod Biomed Online 173:350-359
24. Vajta G, Kuwayama M (2006) Improving cryopreservation systems. Theriogenology 65:236-244
25. Liebermann J, Dietl J, Vanderzwalmen P et al (2003) Recent developments in human oocyte, embryo and blastocyst vitrification: where are we now? Reprod Biomed Online 7:623-633
26. Lassen EC, Muller J, Schmiegelow K et al (2003) Reduced ovarian function in a long-term survivors of radiation and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab 88:5307-5314
27. Meirow D, Nugent D (2001) The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 7:535-543
28. Poniatowski BC, Grimm P, Cohen G (2001) Chemotherapy-induced menopause: a literature review. Cancer Invest 19:641-648
29. Brydoy M, Fossa SD, Dahl O et al (2007) Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncol 46:480-489
30. Meirow D, Epstein M, Lewis H et al (2001) Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations. Hum Reprod 16:632-637
31. Bromer JG, Patrizio P (2008) Preservation and postponement of female fertility. Placenta 29 (Suppl B):200-205. doi:10.1016/j.placenta.2008.07.005
32. Dupas C, Christin-Maitre S (2008) What are the factors affecting fertility in 2008? Ann Endocrinol 69(Suppl 1):S57-S61. doi:10.1016/S0003-4266(08)73970-2
33. Donnez J, Dolmans MM (2015) Ovarian tissue freezing: current status. Curr Opin Obstet Gynecol 27:222-230. doi:10.1097/GC0.0000000000000171
34. Cobo A (2012) Oocyte vitrification: a watershed in ART. Fertil Steril 98:600-601. doi:10. 1016/j.fertnstert.2012.07.1096
35. Donnez J (2013) Introduction: fertility preservation, from cancer to benign disease to social reasons: the challenge of the present decade. Fertil Steril 99:1467-1468. doi:10.1016/j. fertnstert.2013.03.040
36. Cobo A, Bellver J, Domingo J et al (2008) New options in assisted reproduction technology: the Cryotop method of oocyte vitrification. Reprod Biomed Online 17:68-72
37. Bodri D, Guillein JJ, Trullenque M et al (2010) Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing-hormone agonist triggering in high-risk oocyte donor cycles: a prospective, luteal-phase follow-up study. Fertil Steril 93:2418-2420. doi:10.1016/j.fertnstert.2009.08.036
38. Cobo A, Remohi J, Chang CC et al (2011) Oocyte cryopreservation for donor egg banking. Reprod Biomed Online 23:341-346. doi:10.1016/j.rbmo.2011.05.014
39. Bernatsky S, Clarke A, Suissa S (2008) Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 168:378-381. doi:10.1001/archinternmed.2007.107
40. Schroeder JO, Euler H, Loffler H (1987) Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Ann Intern Med 107:344-346
41. Langford C (2003) Wegener's granulomatosis: current and upcoming therapies. Arthritis Res Ther 5:180-191
42. Rauck AM, Grouas AC (1999) Bone marrow transplantation in adolescents. Adolesc Med 10:445-449
43. Berlanda N, Vercellini P, Fedele L (2010) The outcomes of repeat surgery for recurrent symptomatic endometriosis. Curr Opin Obstet Gynecol 22:320-325. doi:10.1097/GCO. 0b013e32833bea15
44. Garcia-Velasco JA, Somigliana E (2009) Management of endometriomas in women requiring IVF: to touch or not to touch. Hum Reprod 24:496-501. doi:10.1093/humrep/den398
45. Lau NM, Huang JY, MacDonald S et al (2009) Feasibility of fertility preservation in young females with Turner syndrome. Reprod Biomed Online 18:290-295
46. Faluyi O, Mackean M, Gourley C et al (2010) Interventions for the treatment of borderline ovarian tumours. Cochrane Database Syst Rev 8:CD007696. doi:10.1002/14651858. CD007696.pub2
47. Herrero L, Pareja S, Aragones M et al (2014) Oocyte versus embryo vitrification for delayed embryo transfer: an observational study. Reprod Biomed Online 29:567-572. doi:10.1016/j. rbmo.2014.07.016
48. Humaidan P, Bredkjaer HE, Bungum L et al (2005) GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 20:1213-1220
49. Gurbuz AS, Gode F, Ozcimen N et al (2014) Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. Reprod Biomed Online 29:541-544. doi:10.1016/j.rbmo.2014.07.022
50. Santos-Ribeiro S, Polyzos NP, Stouffs K et al (2015) Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and "freeze-all": in-depth analysis of genetic predisposition. J Assist Reprod Genet 32(7):1063-1068. doi: 10.1007/s10815-015-0498-y
51. Millin M, Cobo AC, Rodrigo L et al (2010) Redefining advanced maternal age as an indication for preimplantation genetic screening. Reprod Biomed Online 21:649-657. doi:10.1016/j. rbmo.2010.06.020
52. Cobo A, Garrido N, Crespo J et al (2012) Accumulation of oocytes: a new strategy for managing low-responder patients. Reprod Biomed Online 24:424-432. doi:10.1016/j.rbmo. 2011.12.012
53. http://www.ine.es/daco/daco42/idb/idb.htm
54. Nyboe Andersen A, Goossens V, Bhattacharya S et al (2009) Assisted reproductive technology and intrauterine inseminations in Europe, 2005: results generated from European registers by ESHRE: ESHRE. The European IVF Monitoring Programme (EIM), for the European Society of Human Reproduction and Embryology. Hum Reprod 24:1267-1287. doi:10.1093/humrep/ dep035
55. ESHRE Task Force on Ethics and Law, Dondorp W, deWert G et al (2012) Oocyte cryopreservation for age-related fertility loss. Hum Reprod 27:1231-1237. doi: 10.1093/humrep/des029
56. Stoop D, Cobo A, Silber S (2014) Fertility preservation for age-related fertility decline. Lancet 384:1311-1319. doi:10.1016/S0140-6736(14)61261-7
57. Edgar DH, Gook DA (2012) A critical appraisal of cryopreservation (slow cooling versus vitrification) of human oocytes and embryos. Hum Reprod Update 18:536-554. doi:10.1093/ humupd/dms016
58. Rienzi L, Romano S, Albricci L et al (2010) Embryo development of fresh vs vitrified metaphase II oocytes after ICSI: a prospective randomized sibling-oocyte study. Hum Reprod 25:66-73. doi: 10.1093/humrep/dep346
59. Levi PE, Albani E, Morenghi E et al (2013) Comparative analysis of fetal and neonatal outcomes of pregnancies from fresh and cryopreserved/thawed oocytes in the same group of patients. Fertil Steril 100:396-401. doi:10.1016/j.fertnstert.2013.03.038
60. Cobo A, Serra V, Garrido N et al (2014) Obstetric and perinatal outcome of babies born from vitrified oocytes. Fertil Steril 102:1006-1015. doi:10.1016/j.fertnstert.2014.06.019
61. Rienzi L, Cobo A, Paffoni A et al (2012) Consistent and predictable delivery rates after oocyte vitrification: an observational longitudinal cohort multicentric study. Hum Reprod 17:1606-1612. doi:10.1093/humrep/des088
62. Sonmezer M, Oktay K (2006) Fertility preservation in young women undergoing breast cancer therapy. Oncologist 11:422-434
63. Platet N, Cathiard AM, Gleizes M et al (2004) Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 51:55-67
64. Butt AJ, Caldon CE, McNeil CM et al (2008) Cell cycle machinery: links with genesis and treatment of breast cancer. Adv Exp Med Biol 630:189-205
65. Boukaidi SA, Cooley A, Hardy A et al (2012) Impact of infertility regimens on breast cancer cells: follicle-stimulating hormone and luteinizing hormone lack a direct effect on breast cell proliferation in vitro. Fertil Steril 97:440-444. doi:10.1016/j.fertnstert.2011.11.020
66. Oktay K, Hourvitz A, Sahin G et al (2006) Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 91:3885-3890
67. Azim AA, Costantini-Ferrando M, Oktay K (2008) Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 26:2630-2635. doi:10.1200/JCO.2007.14.8700
68. GarciaVelasco JA, Moreno L, Pacheco A et al (2005) Aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril 84:82-87
69. Domingo J, Guillen V, Ayllón Y et al (2013) Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril 97:930-934. doi:10.1016/j.fertnstert.2012.01.093
70. Cakmak H, Katz A, Cedars MI et al (2013) Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril 100:1673-1680. doi:10.1016/ j.fertnstert.2013.07.1992
71. Kuang Y, Hong Q, Chen Q et al (2014) Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril 101:105-111. doi:10.1016/j.fertnstert.2013.09.007
72. Garcia-Velasco JA, Domingo J, Cobo A et al (2013) 5-years experience employing oocyte vitrification to preserve fertility for medical and non-medical indications. Fertil Steril 99:1994-1999. doi:10.1016/j.fertnstert.2013.02.004
73. Cil AP, Bang H, Oktay K (2013) Age-specific probability of live birth with oocyte cryopreservation: an individual patient data meta-analysis. Fertil Steril 100:492-499. doi:10.1016/j. fertnstert.2013.04.023
74. Lawrenz B, Jauckus J, Kupka MS et al (2011) Fertility preservation in >1,000 patients: patient's characteristics, spectrum, efficacy and risks of applied preservation techniques. Arch Gynecol Obstet 283:651-656. doi:10.1007/s00404-010-1772-y